PharmCADD
Busan
About PharmCADD
PharmCADD develops a new drug development platform that uses AI-based protein structure prediction algorithms, MD simulation, and quantum calculation to enable faster drug design. PharmCADD's products include Pharmulator, a consolidated drug discovery platform comprised of five core modules such as protein/RNA 3D structure prediction, drug generation, virtual screening, quantum calculation, and toxicity prediction to generate candidates with higher potential; and PharmVAC, a vaccine development platform that provides optimal solutions to users and clients to design, analyze, and visualize more probable RNA sequences for any vaccine candidates.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $19.8M
- Funding stage: Early Stage Venture
- Last round: Series B (Apr 2021)
- Website: pharmcadd.com
Industries & Categories
Artificial Intelligence (AI), Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/pharmcadd-77838 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.